Canada markets close in 5 hours 54 minutes

Syndax Pharmaceuticals, Inc. (SNDX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.86-0.21 (-0.91%)
As of 10:06AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close23.07
Open23.18
Bid22.80 x 400
Ask23.05 x 400
Day's Range22.71 - 23.40
52 Week Range11.22 - 25.34
Volume73,585
Avg. Volume1,204,895
Market Cap1.942B
Beta (5Y Monthly)1.03
PE Ratio (TTM)N/A
EPS (TTM)-2.98
Earnings DateMay 06, 2024 - May 10, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est35.27
  • PR Newswire

    Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

    Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced completion of enrollment in the AUGMENT-101 pivotal trial cohort of patients with relapsed/refractory (R/R) mutant nucleophosmin (mNPM1) acute myeloid leukemia (AML). Topline data is expected in the fourth quarter of 2024 and could support a supplemental New Drug Application (sNDA) filing for revumenib in R/R mNPM1 AML in the first half of 2025.

  • PR Newswire

    Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

    Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its New Drug Application (NDA) for revumenib, the Company's first-in-class menin inhibitor, for the treatment of adult and pediatric relapsed or refractory (R/R) KMT2A-rearranged (KMT2Ar) acute leukemia. The NDA filing is being reviewed under the FDA's Real-Time Onc

  • PR Newswire

    Syndax Announces Appointment of Steven Closter as Chief Commercial Officer

    Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Steven Closter as Chief Commercial Officer, effective immediately. Mr. Closter will lead the Company's commercial strategy and operations, including marketing, sales, and market access, succeeding Steve Sabus, who is departing for personal reasons.